Subramanian Hariharan Selected Research

temsirolimus

10/2014	Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
3/2014	Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Subramanian Hariharan Research Topics

Disease

19	Renal Cell Carcinoma (Grawitz Tumor) 10/2022 - 01/2009
14	Neoplasms (Cancer) 01/2022 - 08/2002
4	Disease Progression 01/2019 - 08/2002
3	Merkel Cell Carcinoma 01/2020 - 01/2017
2	Hypertension (High Blood Pressure) 05/2013 - 05/2011
2	Fatigue 05/2013 - 03/2012
1	Dyslipidemias (Dyslipidemia) 10/2022
1	Infections 01/2022
1	COVID-19 01/2022
1	Body Weight (Weight, Body) 01/2019
1	Adrenocortical Carcinoma 10/2018
1	Carcinoma (Carcinomatosis) 01/2018
1	Myocarditis (Carditis) 01/2018
1	Non-Muscle Invasive Bladder Neoplasms 01/2018
1	Myocardial Infarction 12/2015
1	Edema (Dropsy) 12/2015
1	Proteinuria 12/2015
1	Hypercholesterolemia 03/2014
1	Neutropenia 03/2014
1	Pneumonia (Pneumonitis) 03/2014
1	Hyperglycemia 03/2014
1	Hypophosphatemia 03/2014
1	Stomatitis 03/2014
1	Inflammation (Inflammations) 03/2014
1	Hand-Foot Syndrome 05/2013
1	Clear-cell metastatic renal cell carcinoma 05/2013
1	Brain Neoplasms (Brain Tumor) 02/2011
1	Cardiotoxicity 04/2008
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2006
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 05/2006
1	Meningioma (Meningiomas) 08/2002
1	Glioblastoma (Glioblastoma Multiforme) 05/2002

Drug/Important Bio-Agent (IBA)

15	Sunitinib (Sutent)FDA Link 10/2022 - 04/2008
6	Axitinib (AG 013736)IBA 10/2022 - 05/2013
6	avelumabIBA 10/2022 - 01/2017
5	B7-H1 AntigenIBA 01/2020 - 01/2017
4	Immune Checkpoint InhibitorsIBA 10/2022 - 01/2017
4	Biomarkers (Surrogate Marker)IBA 10/2022 - 05/2011
3	Sorafenib (BAY 43-9006)FDA Link 10/2014 - 09/2011
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 10/2022 - 10/2014
2	Monoclonal AntibodiesIBA 01/2020 - 01/2018
2	Cisplatin (Platino)FDA LinkGeneric 01/2018 - 05/2006
2	AntibodiesIBA 01/2018 - 01/2017
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2017 - 05/2011
2	temsirolimus FDA Link 10/2014 - 03/2014
2	Tyrosine Kinase InhibitorsIBA 10/2014 - 01/2009
2	Interferon-alpha (Interferon Alfa)IBA 03/2014 - 01/2009
2	Bevacizumab (Avastin)FDA Link 03/2014 - 09/2011
2	InterferonsIBA 09/2011 - 01/2009
2	Irinotecan (Camptosar)FDA LinkGeneric 10/2006 - 05/2006
1	omega-Chloroacetophenone (Mace)IBA 10/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	VaccinesIBA 01/2022
1	BNT162 VaccineIBA 01/2022
1	COVID-19 VaccinesIBA 01/2022
1	LigandsIBA 11/2020
1	Immunoglobulins (Immunoglobulin)IBA 01/2020
1	PlatinumIBA 01/2018
1	pembrolizumabIBA 01/2017
1	CreatinineIBA 12/2015
1	Amylases FDA Link 12/2015
1	TOR Serine-Threonine KinasesIBA 10/2014
1	Gemcitabine FDA Link 10/2006
1	Docetaxel (Taxotere)FDA Link 10/2006
1	Celecoxib (Celebrex)FDA Link 10/2006
1	Etoposide (VP 16)FDA LinkGeneric 05/2006
1	Hydroxyurea (Hydrea)FDA LinkGeneric 08/2002

Therapy/Procedure

11	Therapeutics 10/2022 - 08/2002
3	Drug Therapy (Chemotherapy) 01/2018 - 08/2002
1	Immunotherapy 01/2018
1	Nephrectomy 03/2014
1	Aftercare (After-Treatment) 03/2012
1	Duration of Therapy 08/2002
1	Radiotherapy 08/2002
1	Craniotomy 05/2002